Pseudotyped Viral Vector Development Platform
Pseudotyped viral vector has become an effective tool for the delivery of therapeutic genes to target cells in gene therapy due to their unique properties including very broad tropism, high biosafety, and stability. Our company is committed to providing customers with pseudotyped virus vector development services to develop effective novel gene transfer vectors to accelerate the development of gene therapies for rare diseases.
What are Pseudotyped Viruses?
Pseudotyped viruses are viral particles that are encapsulated in other enveloped viral glycoproteins, but their cellular and histophilic properties are determined by the encapsulated glycoproteins. Pseudotyped viruses have been shown to be a novel gene transfer vector with the advantages of non-cell cycle-dependent integration, easier concentration into high titers than proto-viruses, broad tropism, and safe and efficient transfection of cells, which provides a new way to solve the key problem of vector systems in gene therapy.
Fig.1 Pseudotyping of lentiviral vectors. (Gutierrez-Guerrero, A., et al., 2020)
Applications of Pseudotyped Viral Vectors
Different viral vectors such as retroviruses have a natural host cell population that they can effectively infect but are limited in scope. While adeno-associated viruses (AAV) can infect a relatively wide range of cell types, the difficulty in infecting certain specific cell types limits their use in gene therapy. Limiting or expanding the range of cells sensitive to transduction by gene therapy vectors is essential for the development of effective gene therapies. The development of pseudotyped viruse vectors of enveloped viruses offers an attractive approach to the problem of gene delivery.
Our company uses viral envelope proteins from another virus to produce viral vectors to help our customers restrict or broaden the host cell range to meet the needs of gene delivery in gene therapies for rare diseases. Our services include, but are not limited to:
VSV-G Pseudotyped Viral Vectors Development
Providing vesicular stomatitis virus glycoprotein (VSV-G) to help customers produce stable retroviral vectors, lentiviral vectors and baculoviral vectors for rare disease gene therapy.
Baculovirus GP64 Pseudotyped Viral Vectors Development
Helping customers prepare GP64 pseudotyped lentiviral vectors by pseudotyping with natural or ligand-modified GP64 to reduce cytotoxicity and obtain narrower tropism.
LCMV-GP Pseudotyped Viral Vectors Development
Designing LCMV-WE GP pseudotyped HIV-1 vectors and LCMV-WE GP pseudotyped feline immunodeficiency virus (FIV) vectors to target specific neuronal cells.
Alphavirus Glycoprotein Pseudotyped Viral Vectors Development
Constructing pseudotyped lentiviral vectors using mainly the envelope glycoproteins of Ross River virus (RRV) and Semliki Forest virus (SFV) as gene transfer vectors.
- Competitive pricing and fast turnaround time
- Professional technical support
- Cutting-edge technology and equipment
- High-quality products and services
- Unmatched project management capability
As a leading biotechnology company in the field of gene therapy, our company provides customers with pseudotyping of enveloped and non-enveloped vectors to modify host tropism or increase or decrease the stability of viral particles, accelerating the development of effective gene therapies for rare diseases. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
- Gutierrez-Guerrero, A., et al. "Lentiviral vector pseudotypes: precious tools to improve gene modification of hematopoietic cells for research and gene therapy." Viruses 12.9 (2020): 1016.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.